ERBB2 and non-small cell lung carcinoma: In subgroup analyses, patients with NSCLC (with or without ICB), CRC, EGC, BLAD, hormone receptor–positive/HER2+ BRCA, HNSCC, and OVCA had better OS with high CD8+, PD-1+, CD8+PD-1+, and/or FOXP3+ cells, after risk factor adjustments (Table 1; Data Supplement, Table S3).